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Abstract
Hepatocellular carcinoma (HCC) is now the fifth cancer 
of greatest frequency and the second leading cause of 
cancer related deaths worldwide. Chief amongst the 
risks of HCC are hepatitis B and C infection, aflatoxin 
B1 ingestion, alcoholism and obesity. The latter can 
promote non-alcoholic fatty liver disease (NAFLD), 
that can lead to the inflammatory form non-alcoholic 
steatohepatitis (NASH), and can in turn promote HCC. 
The mechanisms by which NASH promotes HCC are 
only beginning to be characterized. Here in this review, 
we give a summary of the recent findings that describe 
and associate NAFLD and NASH with the subsequent 
HCC progression. We will focus our discussion on 
clinical and genomic associations that describe new 
risks for NAFLD and NASH promoted HCC. In addition, 
we will consider novel murine models that clarify some 
of the mechanisms that drive NASH HCC formation.
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Core tip: Non-alcoholic steatohepatitis (NASH) is a 
metabolic inflammatory disease that can advance to liver 
cancer. Clinical studies have suggested links between 
non-alcoholic fatty liver disease, NASH and progression 
to hepatocellular carcinoma (HCC). Herein, we discuss 
genomic screens that have illustrated new candidate 
genes as markers for increased HCC risk. In addition, 
we present the latest murine models concerning cellular 
stress and inflammation, which have now been shown 
to have a role in promoting liver tumor growth.
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INTRODUCTION
Liver cancer is now the fifth cancer of greatest 
incidence and second leading cause of cancer related 
deaths worldwide[1]. The major risk factors are hepatitis 
B (HBV) and hepatitis C (HCV) that promote fibrosis 
and cirrhosis and ultimately hepatocellular carcinoma 
(HCC). However, in the last 20 years the rising rates of 
obesity have led to the development of the metabolic 
syndrome and in turn non-alcoholic fatty liver disease 
(NAFLD) and the progressed and inflammatory form 
non-alcoholic steatohepatitis (NASH). Experimental and 
population studies have shown links between NAFLD/
NASH and HCC formation. However the mechanisms 
by which NASH transitions to HCC are only beginning 
to be elucidated. NASH has histological features similar 
to alcoholic hepatitis, with prominent fatty deposition 
and fat storage in the liver parenchymal cells, that 
can promote inflammation and necrosis[2,3]. The initial 
theory for the pathogenesis of NASH was known as 
the “two-hit hypothesis”[4]. Here it was suggested 
that hepatic triglyceride accumulation or steatosis, 
increased the susceptibility of the liver to the “second 
injury hit” of changes in inflammatory cytokines and/
or adipokines, mitochrondrial dysfunction and elevated 
oxidative stress, that together promote steatohepatitis 
and fibrosis. Although still relevant it is now clear 
that additional factors including genetic disposition, 
endoplasmic stress, and altered inflammation can 
contribute to the generation of NASH and HCC. Thus, 
within this review we give an update of the relevant 
concepts that have been published in the last 12 mo.
NASH AND ITS RELATIONSHIP TO 
HUMAN HCC RISK
The rates of obesity and the metabolic syndrome are 
increasing worldwide, therefore clinical studies have 
been undertaken to examine for links with NASH 
and HCC. Indeed, in two separate studies completed 
by Wong et al[5,6], have shown that NASH is the 
most rapid growing risk for liver transplantation in 
patients with HCC. In the first study they considered 
61868 patients over the period 2002-2012 and found 
that the proportion of HCV-related HCC increases 
from 43.4% to 49.9%, whereas NASH-related HCC 
increased from 8.3% to 13.5%, an increase of near 
63%. Furthermore, they found that the number of 
NASH-HCC patients undergoing liver transplantation 
increased nearly 4-fold during this period. In their 
second and following study, they analysed the number 
of adults awaiting liver transplantation and found 
that new registrants with NASH increased by 270%, 
compared to alcoholic liver disease (ALD) 45% and 
HCV 14%. Importantly, NASH-HCC patients are less 
likely to undergo liver transplantation and to survive 
for 90 d on the waitlist than patients with HCV, ALD, or 
HCV and ALD. 
Reports concerning US Veterans revealed differing 
trends. In Beste et al[7], they studied the burden of 
cirrhosis and HCC from US Veterans for the period 
2001-2013. They found during this period the 
incidence of HCC increased from 17 per 100000 in 
2002 to 45 per 100000 in 2012, a rise of 265%, and 
within this group the increases were largely driven by 
HCV-related[8].
GENETIC MARKERS OF NASH HCC
As illustrated above HCC is detected later in NASH-
HCC patients and treated less effectively. Thus, there is 
an emphasis within the field to find new predictors of 
HCC and HCC risk in individuals with NASH. Evidence 
supports the concept that genetic factors are involved 
in the predisposition to NAFLD and NASH, and given 
that up to 25% of NASH can progress to HCC, the 
identification of these factors could lead to better 
patient outcomes[9]. 
Genome wide association studies (GWAS) and 
candidate gene studies have imparted greatly on our 
knowledge of the role of genetics in NAFLD/NASH 
pathogenesis. One of the most studied candidates 
to date is a single-nucleotide polymorphism (SNP) 
variant of the gene encoding the enzyme patatin-like 
phospholipase domain containing protein 3 rs738409 
(PNPLA3; missense mutation resulting in an isoleucine 
to methionine substitution at residue 148 [I148M]) 
that has been shown to be associated with NAFLD 
pathogenesis across different patient cohorts[10,11]. 
Critically, in mechanistic studies the overexpression of 
PNPLA3-I148M in cells and mice promoted triglyceride 
accumulation through the disruption of hydrolysis[12]. 
In agreement, the ablation of the PNPLA3 gene in mice 
resulted in reduced hepatic steatosis and triglyceride 
content[13]. Separately as well, this SNP has been 
strongly associated with clinically important factors, 
which include the strength of liver fibrosis and cirrhosis 
as well as the risk of developing NAFLD/NASH-related 
HCC[14-17]. Of special interest is the work of Liu et al[16], 
who showed that the carriage of each copy of the 
rs738409 (G) allele promoted an additive risk of HCC, 
where GG homozygouts have a 5-fold greater risk 
than CC. The link with HCC has been further enforced 
by a recent Japanese study where the authors showed 
that SNP rs738409 located in PNPLA3 was the highest 
risk factor in their patient cohort. Further stratification 
of their group showed that the PNPLA3 G allele was 
significantly higher amongst HCC patients with type 
2 diabetes mellitus. From this group they found a 
significant association between the PNPLA3 G allele 
and the gene for the Juxtaposed with another Zinc 
Finger Protein 1 (JAZF1) rs864745 G allele. JAZF1 
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functions as a transcriptional repressor and has been 
associated with the increased risk of prostate cancer 
and diabetes[18]. Importantly, a recent study has shown 
that JAZF1 overexpression in mice suppressed lipid 
accumulation and decreased droplet size, suggesting 
that JAZF1 plays a critical role in the regulation of lipid 
homeostasis and possibly in the prevention of NAFLD 
and NASH, and thus progression to HCC[19]. Taken 
together these data suggest strong links between SNP 
rs738409 and increased HCC risk, but the mechanism 
through which this SNP can promote HCC risk remains 
open and will require the development of genetic 
murine models.
In 2014 two separate studies identified a new 
rs58542926 C>T genetic variant of the transmembrane 
6 superfamily member 2 gene (TM6SF2), which 
encoded a loss-function substitution of lysine (E) 
to glutamic acid (K) at position 167 (E167K)[20,21]. 
These studies showed that the TM6SF2 variant 
E167K was associated with greater serum levels of 
alanine transaminase, liver injury, and lower levels 
of low-density lipoprotein-cholesterol (LDL-C), 
triglycerides and alkaline phosphatase in patients with 
NAFLD/NASH. Additionally, both papers illustrated 
mechanistically that Tm6sf2 regulates lipogenesis, 
while the treatment of mice with adeno-associated 
virus-mediated short hairpin mRNA reduced plasma 
cholesterol and triglyceride levels (VLDL). Also, it was 
alternatively shown that the overexpression of TM6SF2 
in mice increased fasting cholesterol. In subsequent 
independent studies it was illustrated that the 
inhibition of TM6SF2 in cellular models was associated 
with reduced secretion of triglyceride rich lipoproteins 
and increased triglyceride cellular concentration. 
Conversely TM6SF2 overexpression decreased cellular 
triglyceride concentration and decreased the number 
and size of intracellular lipid droplets[22].
A recent independent study found that TM6SF2 
rs5842926 could be associated with the severity of 
NAFLD related fibrosis, and this was independent of 
the potentially cofounding factors that include gender, 
age, body mass index (BMI), type 2 diabetes and 
the PNPLA3 rs738409 genotype[23]. Given that NASH 
and fibrosis are risk factors for HCC the authors then 
extended their analyses to determine the contribution 
of TM6SF2 rs5842926 to HCC risk. Here they found in 
univariate analyses that TM6SF2 was associated with 
increased risk of progression to NASH-HCC. However, 
this link was not maintained when the cofounding 
factors age, type 2 diabetes and the presence of 
underlying cirrhosis was incorporated into their model. 
Despite these interesting findings, separate 
studies have suggested that TM6SF2 rs5842926 may 
in fact represent a special type of NAFLD. Zhou et 
al[24] examined how TM6SF2 rs5842926 influenced 
the circulating triacylglycerol lipid signatures and 
hepatic or adipose insulin sensitivity in patients. 
They compared the liver fat and circulating fat levels 
between TM6SF2 rs5842926 carriers and non-carriers, 
and found that the liver fat content was 34% higher 
in the carriers than the non-carrier group. However, 
in further investigations the increases in hepatic fat 
content did not coincide with a decrease in whole body 
or hepatic or adipose insulin sensitivity. It was in fact 
associated with reductions in the circulating total levels 
of triacylglycerol lipids when compared to non-carriers. 
This led the authors to suggest that the TM6SF2 
variant represents a metabolically silent variant of 
NAFLD, as the allele is clearly not associated with 
hypertriglyceridemia that is typically associated with 
NAFLD patients[25]. Interestingly, these observations 
also suggest that as TM6SF2 rs5842926 carriers have 
reduced levels of circulating lipids, they could also 
have a reduced risk of cardiovascular disease. In this 
light, the publication of Dongiovanni et al[26], showed 
that TM6SF2 rs5842926 carriers had lower serum lipid 
levels, more-severe steatosis, necroinflammation, 
ballooning and fibrosis, but were in fact protected 
from cardiovascular disease. Taken together these 
data suggest that carriers have greater prevalence for 
NAFLD related liver disease. Whether these patients 
go on and develop a higher risk of NASH HCC will 
need to be determined from larger patients data 
sets. In comparison, those that have the normal 
allele of TM6SF2 have a reduced risk of NAFLD and 
increased risk of cardiovascular disease. Despite these 
indifferent data, studies now need to be performed to 
evaluate whether TM6SF2 rs5842926 carriers have 
associations with other SNPs that can then potentiate 
the characteristic metabolic phenotype observed in 
NAFLD and NASH patients. The combination of these 
additional factors may be a harbinger for increased 
HCC risk.
BIOMARKERS OF NASH HCC
Given the interest in disregulated lipogenesis in 
predicting NASH, research has turned to analyzing the 
proteomic and lipid signature of lipid metabolism in 
NASH-HCC animal models and patients. An interesting 
study considered the change of these factors in the 
hepatocyte-specific PTEN (phosphate and tensin 
homolog deleted from chromosome 10)-deficient 
mouse model, which generates spontaneous NASH 
and HCC[27] and the relationship to human NASH-
HCC. They identified a HCC signature where there 
was upregulated specific lipids within the liver and 
plasma (see within[27] for more detail), and a NASH 
signature of upregulated hepatic C18 fatty acid 
producing elongase (ELOVL6; is responsible for the 
elongation of C16 fatty acids) that was associated 
with elevated oleic, adrenic, and osbond acids, and 
reduced cervonic acid in the liver and plasma and with 
tumor burden. However in response, Kessler et al[28] 
found reduced ELOVL6 gene expression in a majority 
of human liver tumours in a separate human cohort 
when compared to non-tumour tissue. They also saw 
reduced expression of ELOVL6 gene expression in the 
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removed the gene Trim24 (tripartite motif-containing 
24) from all tissues or only from the liver of mice[33]. 
Trim24 gene mediates transcriptional control by 
interacting with the activation function 2 (AF2) region 
of varied nuclear receptors, such as the estrogen, 
retinoic acid, and vitamin D3 receptors and is thought 
to associate with chromatin and heterochromatin-
associated factors. Here the authors found that the 
global loss of Trim24 protein decreased the expression 
of genes involved in oxidation and reduction, steroid, 
fatty acid and lipid metabolism and increased the 
gene expression of genes regulating the unfolded 
protein response, endoplasmic reticulum stress and 
cell cycle pathways. Both the total knock-out and liver 
specific knock-out mice spontaneously developed 
liver lipid filled lesions, steatosis, injury, fibrosis and 
HCC. In contrast in humans elevated histopathological 
expression of Trim24 protein has been associated 
with multiple cancers, including HCC[34]. Nevertheless, 
follow-up studies considering the relative gene 
expression of Trim24 in human HCC and NASH-HCC 
have not yet been published. Thus Trim24’s association 
with human HCC remains open.
New mechanisms
Continuing with same theme of gene regulation, 
new evidence has suggested that over-nutrition and 
metabolic pathways can promote the dysregulation 
of chromatin modifiers and histone post-translational 
modifications to generate abnormal transcriptional 
activity. Through quantitative expression profiling of 
115 chromatin regulators from dietary and genetic 
obesity-promoted HCC, the histone deacetylase 8 
(HDAC8) was found to be significantly upregulated[35]. 
Promoter analyses revealed the HDAC8 promoter to 
have binding sites for the sterol regulatory element-
binding protein-1 (SREBP-1), a master regulator of 
lipogenesis, and both HDAC8 and SREBP-1 were 
upregulated in the livers of mice fed a high fructose 
high carbohydrate diet. Further work revealed that 
HDAC8 promoted insulin resistance and tumour 
growth in vivo. Mechanistically, it was found that 
HDAC8 promoted tumour growth through the 
activation of β-catenin signaling and the repression 
of Wnt antagonists, and was associated with primary 
human NAFLD-associated HCC. Taken together these 
data suggest that targeting cancer-specific critical 
chromatin regulators with small molecular inhibitors 
may aid in treating obesity related HCC.
Fructose
Fructose has been suggested to be a promoter of liver 
cancer. Earlier studies have suggested links (see our 
recent review[36]) but a recent report added weight to 
this concept, showing in mice using the DEN model 
that fructose can promote HCC. Here the authors 
injected DEN and subsequently fed the mice with 
various diets from 6 wk of age until completion at 32 
diethylnitrosamine (DEN) HCC model. Nonetheless, 
the same group then went and extended their 
observations to the methionine and choline deficient 
diet model of NASH, and an elevated C18/C16 fatty 
acid ratio was found. They further focused their 
experiments to human NASH and NASH-HCC patients 
and there they observed that the gene expression of 
ELOVL6 was significantly elevated[29]. Taken together 
these data suggest that lipidomic analyses may be a 
useful way to identify NASH patients who may have a 
higher HCC risk.
Other markers have also been considered for 
NAFLD/NASH. A Chinese group found that the serum 
levels of cytokeratin-18 M30 fragment (Ck-18-M30; a 
marker of hepatocyte apoptosis) fibroblast-21 (FGF-21; 
related to decreasing blood glucose, lipid and insulin 
levels, reversing hepatic steatosis and bettering insulin 
sensitivity), interleukin 1 receptor antagonist (Il-1Ra; 
reduces liver inflammation) and pigment epithelium-
derived factor (PEDF; an independent risk factor of 
fatty liver disease) increased in NAFLD patients, while 
the serum levels of osteoprotegerin [a decoy receptor 
for the receptor activator of nuclear factor kappa B 
ligand (RANKL)] decreased[30]. 
MOLECULAR MOUSE MODELS
Given these findings and the numerous mechanisms 
that have been proposed to promote NASH-HCC a 
number of interesting and seminal studies have been 
published in the last 12 mo outlining new models and 
explanations of NASH HCC biology.
New models
One of the major hypotheses of the field is that 
HCC develops from NASH through obesity, insulin 
resistance, the increased release of inflammatory 
factors and autophagy[31]. However, there is no 
standard mouse model that addresses some of these 
changes. Recently, De Minicis et al[32], published a new 
murine model of NASH HCC development that was 
associated with peripheral insulin resistance. Here 
they treated mice with combinations of a choline-
deficient L-amino-acid-defined-diet (CDAA) and a low 
dose of carbon tetrachloride (CCl4) and observed that 
after one month the mice developed peripheral insulin 
resistance and at 3 mo extensive steatosis in CDAA 
and CDAA + CCl4 groups. At 6 mo both groups had 
increased and equal levels of fibrosis and steatosis 
and HCC. However, by 9 mo all CDAA+CCl4 treated 
mice had HCC, whereas only 40% of the CDAA group 
had HCC. Significantly, cirrhosis was absent and there 
was decreased gene expression of PTEN and positive 
histology for AKT, c-Myc and glypican-3, similar to that 
seen in human NASH HCC, suggesting that this model 
may be valuable for examining the role of potential 
gene candidates in HCC development.
Another model that has been recently published 
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wk. It was found that high fat diets containing lard 
or coconut oil increased tumor burden by 1.5- and 
2.2-fold, respectively. Mice fed a high fructose diet had 
approximately 2-fold more tumor burden than control 
mice. In all diet groups, AMPK and mTORC1 activity 
was detected, but no diet specific changes were noted 
for sirtuin 1 (SIRT1) and p53, suggesting that other 
mechanisms are responsible for the enhanced tumor 
growth[37]. 
Endoplasmic stress
The DEN model of HCC has been well utilized and 
has been shown in conjunction with a high fat diet 
(HFD) to promote low-grade liver inflammation in 
association with tumor necrosis factor (TNF) and 
interleukin-6 (IL-6) expression. The absence of 
these factors in mice further enhances HCC growth, 
however in wild-type mice the progression to NASH 
does not occur[38]. In an effort to identify factors that 
promote the progression to NASH, Nakagawa and 
colleagues[39] studied the role of endoplasmic stress 
(ER) in HCC progression. To do this they utilized the 
major urinary protein-urokinase plasminogen activator 
(MUP-uPA) transgenic mouse model. This mouse 
overexpresses the uPA protein that then accumulates 
in the hepatocyte endoplasmic reticulum, to promote 
ER stress and hepatic lesions. Compared to wild-type 
mice the MUP-uPA mice when fed a HFD developed 
NASH-like disease that spontaneously progressed to 
HCC. They observed the upregulation of several stress 
ER markers in the hepatocytes of MUP-uPA mice. 
These included C/EBP homologous protein (CHOP), 
glucose-regulated protein 78 (GRP78), spliced x-box 
binding protein (sXBP1), phosphorylated Eukaryotic 
Initiation Factor 2 (p-eIF2), phosphorylated inositol-
requiring enzyme 1α (p-IRE1α), and phosphorylated 
janus kinase (p-JNK). ER stress also promoted SREBP1 
expression, to enhance lipogenesis and ultimately 
reactive oxygen species production that in turn affects 
genomic instability. The authors also identified that 
inflammation played a role as TNF production was 
increased in HFD-fed MUP-uPA livers and was localized 
to macrophages. Subsequent breeding of the MUP-
uPA mice with TNF receptor (TNFR1)-deficient mice 
to generate MUP-uPA TNFR1-/- mice, and subsequent 
HFD feeding reduced HCC development as compared 
to MUP-uPA mice. Finally, the treatment of MUP-uPA 
mice with the TNF antagonist Etanercept (commercial 
name: Enbrel) reduced tumour growth by 2-fold, 
suggesting that the application of such a therapy may 
be useful for NASH and NASH-HCC patients.
In a separate report the role of Gp78, an E3 
Ubiquitin Ligase has been examined in NASH and liver 
cancer[40]. Gp78 regulates endoplasmic reticulum-
associated degradation by ubiquitinating misfolded ER 
proteins. Normally, misfolded proteins are exported 
from the ER to the cytosol where they are degraded by 
the ubiquitin-proteasome machinery, of which Gp78 is 
a part. If the unfolded protein response is delayed or 
insufficient there may be pathological outcomes such 
as that seen in the CHOP knock-out mouse model 
where HCC is potentiated after treatment with DEN[41]. 
Here the authors found that the ablation of Gp78 
induced obesity, hepatic steatosis and inflammation 
in aged mice. Furthermore they observed that the 
loss of Gp78 induced steatosis through SREBP-1 
activation. Finally, they found that 20% of the mice 
developed liver tumours, suggesting that Gp78 could 
be considered as a tumour suppressor. Given these 
data they decided to explore whether Gp78 could be 
used as a progression marker and from a tissue array 
of human HCC, they found that Gp78 expression was 
significantly lower in the tumour than in normal liver 
tissues. In sum these data suggest a role for Gp78 in 
NASH HCC, and further studies are required to readily 
associate it with human NASH HCC pathology.
Inflammation
A major feature in the transition from NAFLD to NASH 
is the appearance of hepatic inflammation. A factor 
that is known to exacerbate NAFLD and NASH is 
choline deficiency. In humans, low levels of choline 
intake are associated with reduced hepatic lipoprotein 
secretion, mitochondrial dysfunction and thus oxidative 
damage, and ER stress. Given that the injection of 
mice with DEN combined with HFD promoted more 
HCC and increased hepatic inflammation, a study was 
instigated where mice were given a choline deficient 
diet in combination with a HFD diet (CD-HFD)[42]. It 
was found that these mice attained features of the 
metabolic syndrome, hepatic damage and NASH, and 
the hepatic infiltration and activation of immune cells. 
Most notably there were increased numbers of CD8+ 
T cells and natural killer T cells (NKT), similar to that 
seen in NASH patients. Through a series of elegant 
mouse experiments the authors showed that NKT cells 
mediate hepatic lipid uptake through the secretion of 
LIGHT (lymphotoxin-like, exhibits inducible expression, 
and competes with HSC glycoprotein D 9(gD) for 
HVEM, a receptor expressed by T lymphocytes) and 
subsequent activation of the lymphotoxin-β receptor 
on hepatocytes. Importantly, they showed that the 
CD8+ T cells and NKT cells regulate the formation of 
NASH and NASH induced HCC in mice, and that the 
elevated expression of LIGHT, CD8+ T cells and NKT 
was associated with steatosis related human liver 
diseases. In this light, the data suggest that a therapy 
targeting the reduction of CD8+ T cells and/or NKT 
in NASH patients has the potential to reduce disease 
progression, minimize hepatic damage and ultimately 
NASH HCC.
New concepts
Normally, hepatocytes have the ability to increase 
the number of chromosome sets, a process called 
polyploidization, to result in an increase in the number 
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of nuclei per cell, being diploid (binuclear), tetratploid 
(4 nuclei) and octoploid (8 nuclei). This phenomenon 
is not completely understood, but has also been shown 
to be associated with genomic stress and pathologies 
like cancer[43,44]. Apart from promoting ER stress, 
NAFLD and NASH can promote oxidative stress and 
this is believed to be in part through cytochrome 
P450 2E1 (CYP2E1) as it metabolises C10-C20 fatty 
acids, that in turn generates ROS[45]. In a recent 
report it was shown that oxidative stress can promote 
pathologic polyploidization in murine models of NASH 
and patients samples[46], and was associated with 
the activation of a G2/M DNA damage checkpoint. 
Interestingly, they treated leptin deficient mice with an 
antioxidant in vivo and the extent of oxidative stress 
and polyploidy was greatly reduced. Taken together 
these data suggest that polyploidy may be one of the 
early events of NAFLD and could contribute to the 
progression to NASH. 
Potential therapeutics
Currently only one pharmacological agent the multi-
kinase inhibitor Sorafenib, prolongs the survival of 
patients with HCC. Nonetheless, median survival is only 
improved by a paltry 12 wk, emphasizing an urgent 
need to develop new and improved therapies[47,48]. 
A factor that has been shown to contribute to NASH 
pathogenesis is excess free cholesterol. Given that 
statins are readily prescribed to reduce cholesterol 
synthesis and thus serum levels, a recent study has 
collated statin use and NASH risk[49]. Here the authors 
examined the relationship between statin use, genetic 
risk factors and hepatic damage of 1201 European 
patients. Statin use was noted in 107 patients, and 
it was found that these patients were protected from 
steatosis, NASH and fibrosis stage F2-F4. Significantly, 
in statin treated patients, steatosis was reduced by 
48%-91% and NASH decreased by 36%-76% and 
significant fibrosis was nearly halved. Nevertheless, 
with regards to genetic predisposition, the presence of 
the I148M PNPLA3 allele blunted the effect of statins. 
Taken together, the use of statins is beneficial in NASH 
patients without the I148M PNPLA3 allele and will thus 
likely reduce NASH HCC risk. 
The mammalian target of rapamycin (mTOR) 
has been identified to promote growth in a majority 
of liver cancers[50]. mTOR consists of two distinct 
complexes, mTORC1 and mTORC2, and mTORC1 is 
sensitive to rapamycin and activates down-stream 
targets to regulate cellular growth and metabolism 
that is activated by nutrients and growth factors[51]. 
Moreover, studies have shown that chronic mTORC1 
activation is associated with obesity, hepatosteatosis 
and insulin resistance[52]. Likewise mTOR has been 
shown to play a key role in liver cancer growth, and 
agents such as rapamycin and its analogs Everolimus 
and Temsirolimus, which suppress mTORC1 have 
been trialed to treat HCC[53]. However, the results to 
date using rapalogs as a single-agent cancer agent in 
human HCC have not been encouraging. By example, 
a phase 3 study showed that Everolimus increased the 
incidence of hepatic injury and did not extend survival 
in patients with advanced HCC[54-57]. To examine 
for reasons why mTORC1 inhibition is not suitable 
in patients, Umemura et al[58] treated mice with 
rapamycin and generated mice with the hepatocyte 
specific deletion of the mTORC1 subunit raptor. They 
found that rapamycin treatment increased hepatocyte 
cell death, IL-6 expression and signal transducer and 
activator of transcription 3 (STAT3) activation, and 
reduced SREBP1 and IL-10 expression, and in sum 
increased hepatic inflammation. Similarly, the loss of 
Raptor in the hepatocytes promoted cell hepatocyte 
cell death and inflammation, and significantly after 
the injection of DEN, enhanced obesity-promoted 
hepatocarcinogenesis. Further, they found in these 
mice, that Raptor deficiency promotes liver fibrosis 
and does not improve metabolic parameters in obese 
mice. Given these data and the clinical trial data, single 
mTOR inhibition approaches are not useful for treating 
HCC and NASH HCC. However, it is likely that due to 
feedback mechanisms that AKT activation caused by 
mTOR inhibition can be a culprit of these phenotypes. 
Moreover, it remains to be determined whether a more 
targeted or a combinatorial approach could be useful 
to treat NASH HCC.
Finally, given that NASH HCC is related to over-
nutrition an obvious therapeutic approach would be to 
increase energy utilisation. Here hepatocyte specific 
PTEN-deficient mice that spontaneously develop 
steatohepatitis and HCC were divided into sedentary 
or exercise groups[59]. After 32 wk of regular exercise, 
71% of the exercised groups developed tumor nodules 
greater than 15 mm3, whereas 100% of the sedentary 
group developed tumors of this size. Significantly, the 
number of tumours and tumour volume was reduced 
in the exercise group. There was no change in hepatic 
steatosis in the exercise group, tumor cell proliferation 
decreased and the phosphorylation of AMPK and raptor 
increased. Taken together, these data suggest that 
exercise can reduce HCC development and load in a 
mouse model, and suggest that patients who have a 
higher risk for NASH HCC, could increase their physical 
activity to prevent HCC development.
CONCLUSION
Taken together here we have reflected on the 
strength of clinical data and genetic mutations found 
in patients that illustrate the connection between 
NAFLD and NASH, and increased liver cancer risk. 
Significantly, in the last 12 mo studies have come 
together to suggest that TM6SF2 rs5842926 carriers 
have a silent phenotype. It will be interesting to see 
if other mutations are associated with these carriers 
to promote progression towards HCC. Significantly, 
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at the molecular level, cellular and murine models 
have shown the importance of gene modifications, 
cellular stress and inflammation in driving the HCC 
progression. It remains open whether therapeutics can 
be developed with limited off target effects to limit HCC 
growth. In this light, for many years it was assumed 
that limiting the activity of the mTOR pathway would 
be a strategy to treat liver cancer. Clinical trials 
targeting mTOR in HCC have been disappointing. 
Moreover, studies presented here now show that 
targeting mTOR can promote inflammation and in the 
instance of genetic ablation of Raptor, increase HCC 
load after DEN injection. Nevertheless, these studies 
have not addressed the issues of feedback through 
the mTOR pathway and thus it remains open, whether 
mTOR targeted therapy in conjunction with other 
therapeutics or simply a better delivery system could 
be used to treat NASH HCC patients. In sum, much 
is needed to be done to further our understanding of 
the mechanisms in play that promote NASH HCC and 
to develop new therapeutics to treat this devastating 
disease.
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